Copyright
©The Author(s) 2021.
World J Gastroenterol. Jul 28, 2021; 27(28): 4504-4535
Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4504
Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4504
Suggestions | |
(1) Starting with corticosteroids and immunomodulators should proceed; and (2) Risk benefit ratio assessments should be carried out | |
Patients on immunosuppressive treatment and not infected with COVID-19 | Decreases or adjustment of doses is not advisable |
Patients infected with COVID-19 on immunosuppressive drugs | (1) Reduce corticosteroids dose after specialist physician (consider tapering to prevent adrenal insufficiency); and (2) Decreasing the doses of cyclosporine, mycophenolate, and azathioprine is recommended in severe COVID-19 (especially patients with lymphopenia) |
Patients requiring initiation of immunosuppressive agents | Starting treatment is suggested in these patients regardless of COVID-19 status |
- Citation: Mohamed DZ, Ghoneim MES, Abu-Risha SES, Abdelsalam RA, Farag MA. Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management. World J Gastroenterol 2021; 27(28): 4504-4535
- URL: https://www.wjgnet.com/1007-9327/full/v27/i28/4504.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i28.4504